Table 2.
Results of pathway-based analysis in IS and MS GWAS datasets showing significant and shared IS-MS pathways in VEGAS in PANTHER, REACTOME and WikiPathways.
| Pathway ID | Description | IS | MS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C | O | E | R | p-value | FDR | C | O | E | R | p-value | FDR | ||
| PANTHER | |||||||||||||
| P00012 | Cadherin signaling pathway | 153 | 22 | 8.80 | 2.50 | 3.34E-05 | 2.51E-03 | 153 | 27 | 12.1 | 2.23 | 3.32E-05 | 2.49E-03 |
| P00057 | Wnt signaling pathway | 294 | 31 | 16.9 | 1.83 | 3.63E-04 | 1.36E-02 | 294 | 38 | 23.2 | 1.64 | 9.17E-04 | 2.29E-02 |
| REACTOME | |||||||||||||
| R-HSA-8876198 | RAB GEFs exchange GTP for GDP on RABs | 90 | 12 | 4.51 | 2.66 | 1.72E-03 | 2.45E-01 | 90 | 10 | 5.50 | 1.82 | 4.75E-02 | 3.32E-01 |
| R-HSA-1839124 | FGFR1 mutant receptor activation | 31 | 6 | 1.56 | 3.86 | 3.90E-03 | 2.45E-01 | 31 | 5 | 1.90 | 2.64 | 3.82E-02 | 2.87E-01 |
| R-HSA-111885 | Opioid signaling | 85 | 10 | 4.26 | 2.34 | 9.84E-03 | 3.71E-01 | 85 | 10 | 5.20 | 1.92 | 3.40E-02 | 2.70E-01 |
| R-HSA-2219530 | Constitutive signaling by aberrant PI3K in cancer | 65 | 8 | 3.26 | 2.45 | 1.55E-02 | 4.02E-01 | 65 | 10 | 3.97 | 2.52 | 5.76E-03 | 9.38E-02 |
| R-HSA-445144 | Signal transduction by L1 | 21 | 4 | 1.05 | 3.79 | 1.90E-02 | 4.20E-01 | 21 | 4 | 1.28 | 3.11 | 3.61E-02 | 2.80E-01 |
| R-HSA-1500931 | Cell-cell communication | 141 | 13 | 7.07 | 1.84 | 2.47E-02 | 4.20E-01 | 141 | 14 | 8.62 | 1.62 | 4.95E-02 | 3.43E-01 |
| R-HSA-6811434 | COPI-dependent golgi-to-ER retrograde traffic | 98 | 10 | 4.92 | 2.03 | 2.48E-02 | 4.20E-01 | 98 | 12 | 5.99 | 2.00 | 1.61E-02 | 1.79E-01 |
| R-HSA-373753 | Nephrin interactions | 23 | 4 | 1.15 | 3.47 | 2.59E-02 | 4.23E-01 | 23 | 5 | 1.41 | 3.55 | 1.13E-02 | 1.48E-01 |
| R-HSA-6811558 | PI5P, PP2A and IER3 Regulate PI3K/AKT signaling | 87 | 9 | 4.36 | 2.06 | 2.99E-02 | 4.70E-01 | 87 | 11 | 5.32 | 2.07 | 1.66E-02 | 1.79E-01 |
| R-HSA-2219528 | PI3K/AKT signaling in cancer | 90 | 9 | 4.51 | 1.99 | 3.61E-02 | 5.28E-01 | 90 | 13 | 5.50 | 2.36 | 3.11E-03 | 5.59E-02 |
| R-HSA-913531 | Interferon signaling | 199 | 16 | 9.98 | 1.60 | 4.22E-02 | 5.61E-01 | 199 | 21 | 12.17 | 1.73 | 1.01E-02 | 1.41E-01 |
| R-HSA-877300 | Interferon gamma signaling | 93 | 9 | 4.67 | 1.93 | 4.32E-02 | 5.61E-01 | 93 | 15 | 5.69 | 2.64 | 4.80E-04 | 1.21E-02 |
| R-HSA-6783589 | Interleukin-6 family signaling | 27 | 4 | 1.35 | 2.95 | 4.40E-02 | 5.61E-01 | 27 | 8 | 1.65 | 4.85 | 1.47E-04 | 5.63E-03 |
| R-HSA-199418 | Negative regulation of the PI3K/AKT network | 94 | 9 | 4.72 | 1.91 | 4.58E-02 | 5.75E-01 | 94 | 11 | 5.75 | 1.91 | 2.79E-02 | 2.39E-01 |
| WIKI PATHWAYS | |||||||||||||
| WP2203 | Thymic stromal Lymphopoietin (TSLP) signaling pathway | 47 | 7 | 2.60 | 2.69 | 1.39E-02 | 6.89E-01 | 47 | 14 | 3.21 | 4.36 | 1.62E-06 | 1.19E-04 |
Same conventions as in Table 1.